1. Search Result
Search Result
Targets Recommended: ATGL
Results for "

triglyceride

" in MCE Product Catalog:

48

Inhibitors & Agonists

1

Screening Libraries

2

Dye Reagents

3

Biochemical Assay Reagents

14

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas
  • HY-112132
    Palmitodiolein

    triglyceride POO; Glycerol dioleate palmitate; 1,2-Dioleoyl-3-palmitoylglycerol

    Others Metabolic Disease
    Palmitodiolein (Triglyceride POO) is a triacylglycerol which is present in vegetable oils.
  • HY-113955
    CP-346086

    Others Metabolic Disease
    CP-346086 is a potent and orally active microsomal triglyceride transfer protein (MTP) inhibitor, with an IC50 of 2.0 nM for human and rodent MTP. CP-346086 can lower plasma cholesterol and triglycerides in vivo.
  • HY-113955A
    CP-346086 dihydrate

    Others Metabolic Disease
    CP-346086 dihydrate is a potent and orally active microsomal triglyceride transfer protein (MTP) inhibitor, with an IC50 of 2.0 nM for human and rodent MTP. CP-346086 dihydrate can lower plasma cholesterol and triglycerides in vivo.
  • HY-119964
    Cetaben

    Others Cardiovascular Disease
    Cetaben is a PPARα-independent peroxisome proliferator. Cetaben is a non-fibrate hypolipidemic drug and potently reduces the concentration of cholesterol and triglycerides.
  • HY-N8214
    Isorhamnetin 3-O-β-D-glucose-7-O-β-D-gentiobioside

    Others Cardiovascular Disease
    Isorhamnetin 3-O-β-D-glucose-7-O-β-D-gentiobioside is a bioactive constituent that can be found in the seeds of Lepidium apetalum Willd. Isorhamnetin 3-O-β-D-glucose-7-O-β-D-gentiobioside exhibits significant triglyceride (TG)-lowering effects in HepG2 cells.
  • HY-N9535
    tert-OMe-byakangelicin

    Others Metabolic Disease
    tert-OMe-byakangelicin is a coumarin that can enhances the adrenaline-induced lipolytic effect and inhibits insulin-stimulated triglyceride synthesis from glucose in fat cells.
  • HY-135297
    Mono-and diglycerides

    Others Others
    Mono-and diglycerides is formed by triglycerides being broken down by pancreatic lipase in the gastrointestinal lumen. Mono-and diglycerides is a food additive used as a nonionic emulsifier and mainly present in food fats.
  • HY-133556
    IQZ23

    AMPK Metabolic Disease
    IQZ23 inhibits adipocyte differentiation via AMPK pathway activation. IQZ23 exerts a high efficacy in decreasing the triglyceride level (EC50=0.033 μM) in 3T3-L1 adipocytes. IQZ23 could be used for the research of obesity and related metabolic disorders.
  • HY-111620
    Ervogastat

    PF-06865571

    Acyltransferase Metabolic Disease Inflammation/Immunology
    Ervogastat (PF-06865571) is a potent and well-tolerated diacylglycerol acyltransferase 2 inhibitor (DGAT2i). Ervogastat alone reduces steatosis and hepatic triglyceride levels in non-alcoholic steatohepatitis (NASH). Ervogastat combination with Clesacostat (an acetyl CoA-carboxylase inhibitor (ACCi)) can be used for the research of NASH with liver fibrosis therapy.
  • HY-W011404
    Tributyrin

    Glyceryl tributyrate

    Apoptosis Metabolic Disease
    Tributyrin (Glyceryl tributyrate), a neutral short-chain fatty acid triglyceride, is a stable and rapidly absorbed prodrug of Butyric Acid. Tributyrin diffuses through biological membranes and is metabolized by intracellular lipases, releasing effective butyrate directly into the cell in vivo. Tributyrin has potent antiproliferative, proapoptotic and differentiation-inducing effects.
  • HY-17504C
    (3R,5R)-Rosuvastatin

    HMG-CoA Reductase (HMGCR) Potassium Channel Autophagy Metabolic Disease Cardiovascular Disease
    (3R,5R)-Rosuvastatin is the (3R,5R)-enantiomer of Rosuvastatin. Rosuvastatin is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin is very effective in lowering low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.
  • HY-17504D
    (3S,5R)-Rosuvastatin

    HMG-CoA Reductase (HMGCR) Potassium Channel Autophagy Metabolic Disease Cardiovascular Disease
    (3S,5R)-Rosuvastatin is the (3S,5R)-enantiomer of Rosuvastatin. Rosuvastatin is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin is very effective in lowering low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.
  • HY-N0686
    Pseudoprotodioscin

    Fatty Acid Synthase (FASN) MicroRNA Metabolic Disease
    Pseudoprotodioscin, a furostanoside, inhibits SREBP1/2 and microRNA 33a/b levels and reduces the gene expression regarding the synthesis of cholesterol and triglycerides.
  • HY-N6626
    Pyraclostrobin

    Fungal Bacterial Infection Metabolic Disease
    Pyraclostrobin is a strobilurin fungicide that inhibits mitochondrial complex III of fungal and mammalian cells. Pyraclostrobin induces triglyceride accumulation and triglyceride accumulation in 3T3-L1 cells.
  • HY-N7055
    Trierucin

    Endogenous Metabolite Metabolic Disease
    Trierucin is a trierucic acid triglyceride from the seed oil.
  • HY-U00329
    Implitapide Racemate

    Others Metabolic Disease Cardiovascular Disease
    Implitapide Racemate is the racemate of Implitapide. Implitapide is a microsomal triglyceride transfer protein (MTP) inhibitor.
  • HY-106130
    Implitapide

    AEGR 427

    Others Metabolic Disease Cardiovascular Disease
    Implitapide (AEGR 427) is a microsomal triglyceride transfer protein (MTP) inhibitor.
  • HY-U00270
    CP-319340(free base)

    Others Metabolic Disease
    CP-319340 free base is a microsomal triglyceride transfer protein (MTP) inhibitor.
  • HY-N2118
    Bilobetin

    PPAR PKA Metabolic Disease
    Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity.
  • HY-U00264
    2-γ-Linolenoyl-1,3-dilinoleoyl-sn-glycerol

    Others Metabolic Disease
    2-γ-Linolenoyl-1,3-dilinoleoyl-sn-glycerol is a triglyceride.
  • HY-W010031
    1-Methyluric acid

    Endogenous Metabolite Metabolic Disease
    1-Methyluric acid acts on the urinary bladder mucosa and increases the blood glucose, insulin, triglyceride, and cholesterol levels.
  • HY-100333
    PF-02575799

    Others Metabolic Disease
    PF-02575799 is a microsomal triglyceride transfer protein (MTP) inhibitor with an IC50 of 0.77±0.29 nM.
  • HY-17504A
    Rosuvastatin

    ZD 4522

    HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Metabolic Disease Cardiovascular Disease
    Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin is very effective in lowering low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.
  • HY-16343
    NB-598

    Others Metabolic Disease
    NB-598 is a potent and competitive inhibitor of squalene epoxidase (SE), and suppresses triglyceride biosynthesis through the farnesol pathway.
  • HY-15859
    Atglistatin

    ATGL Metabolic Disease
    Atglistatin is a selective adipose triglyceride lipase (ATGL) inhibitor which inhibits lipolysis with an IC50 of 0.7 μM in vitro.
  • HY-16343C
    NB-598 Maleate

    Others Metabolic Disease
    NB-598 Maleate is a potent and competitive inhibitor of squalene epoxidase (SE), and suppresses triglyceride biosynthesis through the farnesol pathway.
  • HY-16343A
    NB-598 hydrochloride

    Others Metabolic Disease
    NB-598 hydrochloride is a potent and competitive inhibitor of squalene epoxidase (SE), and suppresses triglyceride biosynthesis through the farnesol pathway.
  • HY-17504
    Rosuvastatin Calcium

    Rosuvastatin hemicalcium; ZD 4522 Calcium

    HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Metabolic Disease Cardiovascular Disease
    Rosuvastatin Calcium (Rosuvastatin hemicalcium) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin Calcium potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin Calcium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Calcium is very effective in lowering low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.
  • HY-14667
    Lomitapide

    AEGR-733; BMS-201038

    Others Cardiovascular Disease
    Lomitapide (AEGR-733; BMS-201038) is a potent inhibitor of microsomal triglyceride-transfer protein (MTP) with an IC50 of 8 nM in vitro.
  • HY-U00070
    Dirlotapide

    CP742033; Slentrol

    Others Metabolic Disease
    Dirlotapide (CP742033) is a gut-selective inhibitor of microsomal triglyceride transfer protein (MTP) that reliably produces weight loss in obese dogs.
  • HY-14668
    Lomitapide mesylate

    AEGR-733 mesylate; BMS-201038 mesylate

    Others Cardiovascular Disease
    Lomitapide mesylate(AEGR-733; BMS-201038) is an inhibitor of microsomal triglyceride-transfer protein (MTP) wtih in vitro IC50 of 8 nM.
  • HY-B1189
    Meglutol

    Dicrotalic acid; 3-Hydroxy-3-methylglutaric acid

    HMG-CoA Reductase (HMGCR) Autophagy Endogenous Metabolite Cardiovascular Disease
    Meglutol is an antilipemic agent which lowers cholesterol, triglycerides, serum beta-lipoproteins and phospholipids, and inhibits the activity of hydroxymethylglutarryl CoA reductases, which is the rate limiting enzyme in the biosynthesis of cholesterol.
  • HY-50665
    LY518674

    LY-674

    PPAR Metabolic Disease
    LY518674 is a potent, selective PPARα antagonist, with an EC50 of 42 nM for human PPARα. LY518674 reduces triglycerides in and increased HDL-C and is used for the treatment of atherosclerosis.
  • HY-129098
    DMHCA

    LXR Metabolic Disease
    DMHCA, a potent and selective LXR agonist, specifically activates the cholesterol efflux arm of the LXR pathway without stimulating triglyceride synthesis. DMHCA has anti-inflammatory effects and can be used for the research of cholesterol homeostasis diabetes.
  • HY-117549
    Ibrolipim

    NO-1886

    Others Cardiovascular Disease
    Ibrolipim (NO-1886) is an orally active lipoprotein lipase (LPL)-promoting agent. Ibrolipim decreases plasma triglycerides, increases high-density lipoprotein cholesterol levels. Ibrolipim has renoprotective and hypolipidemic effects.
  • HY-W012946
    2-Furoic acid

    Furan-2-carboxylic acid

    ATP Citrate Lyase Acyltransferase Endogenous Metabolite Metabolic Disease
    2-Furoic acid (Furan-2-carboxylic acid) is an organic compound produced through furfural oxidation. 2-Furoic acid exhibits hypolipidemic effet, lowers both serum cholesterol and serum triglyceride levels in rats.
  • HY-N8181
    1,3-Linolein-2-Olein

    Parasite Infection
    1,3-Linolein-2-Olein, a triglyceride, is an antileishmanial drug. 1,3-Linolein-2-Olein inhibits promatigotes of the parasite (IC50=0.079 ug/ml) and inhibits the growth of amastigotes (IC50= 40.03 ug/ml).
  • HY-N6660
    Tricaprin

    Glyceryl tridecanoate

    Endogenous Metabolite Metabolic Disease
    Tricaprin (Glyceryl tridecanoate) is an orally available precursor of decanoic acid (DA) and can be hydrolyzed to DA. Tricaprin (Glyceryl tridecanoate) is a major component of medium chain triglyceride (MCT) with antiandrogen and antihyperglycemic properties.Tricaprin (Glyceryl tridecanoate) has a safe use in in foods, drugs, cosmetics as an additive.
  • HY-109567
    Gemcabene

    PD-72953

    Others Metabolic Disease Inflammation/Immunology
    Gemcabene (PD-72953), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity.
  • HY-109567A
    Gemcabene calcium

    PD-72953 calcium

    Others Metabolic Disease Inflammation/Immunology
    Gemcabene calcium (PD-72953 calcium), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity.
  • HY-N5097
    13-Oxo-9E,11E-octadecadienoic acid

    PPAR Metabolic Disease
    13-Oxo-9E,11E-octadecadienoic acid, an isomer of 9-oxo-ODA, is a potent PPARα activator derived from tomato juice. 13-Oxo-9E,11E-octadecadienoic acid decreases plasma and hepatic triglyceride in obese diabetic mice.
  • HY-16278
    Pradigastat

    LCQ-908

    Acyltransferase Metabolic Disease
    Pradigastat (LCQ-908) is a potent, selective and orally active diacylglycerol acyltransferase 1 (DGAT1) inhibitor. Pradigastat has anti-obesity and anti-diabetic effects.
  • HY-123039
    CP-532623

    CETP Metabolic Disease
    CP-532623 is a CETP inhibitor and elevates high-density lipoprotein cholesterolion. CP-532623 is a close structural analogue of Torcetrapib. CP-532623 has highly lipophilic properties.
  • HY-135425
    10,12-Tricosadiynoic acid

    Acyltransferase Metabolic Disease
    10,12-Tricosadiynoic acid is a highly specific, selective, high affinity and orally active acyl-CoA oxidase-1 (ACOX1) inhibitor. 10,12-Tricosadiynoic acid can treat high fat diet- or obesity-induced metabolic diseases by improving mitochondrial lipid and ROS metabolism.
  • HY-116699
    CP-868388 free base

    PPAR Metabolic Disease Inflammation/Immunology Neurological Disease
    CP-868388 free base is a potent, selective and orally active PPARα agonist with a Ki value of 10.8 nM. CP-868388 free base has little or no affinity for PPARβ (Ki of 3.47 μM) and PPARγ. CP-868388 free base has hypolipidemic and anti-inflammatory actions.
  • HY-W009732
    Sinapinic acid

    Sinapic acid

    HDAC Angiotensin-converting Enzyme (ACE) Reactive Oxygen Species Apoptosis Cancer Metabolic Disease
    Sinapinic acid (Sinapic acid) is a phenolic compound isolated from Hydnophytum formicarum Jack. Rhizome, acts as an inhibitor of HDAC, with an IC50 of 2.27 mM, and also inhibits ACE-I activity. Sinapinic acid posssess potent anti-tumor activity, induces apoptosis of tumor cells. Sinapinic acid shows antioxidant and antidiabetic activities. Sinapinic acid reduces total cholesterol, triglyceride, and HOMA-IR index, and also normalizes some serum parameters of antioxidative abilities and oxidative damage in ovariectomized rats.
  • HY-12089
    Torcetrapib

    CP-529414

    CETP Endocrinology
    Torcetrapib (CP-529414) is a selective, potent cholesteryl ester transfer protein (CETP) inhibitor. A typical inhibition curve for whole human plasma, having a CETP concentration of 37 nM.
  • HY-17504AS
    Rosuvastatin D3

    ZD 4522 D3

    HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Metabolic Disease Cardiovascular Disease
    Rosuvastatin D3 (ZD 4522 D3) is a deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals.